Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03437070
Title Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Marilyn Huang
Indications

leiomyosarcoma

Therapies

Doxorubicin + Olaratumab + Trabectedin

Age Groups: adult | senior
Covered Countries


No variant requirements are available.